NB
MCID: NRB001
MIFTS: 71

Neuroblastoma (NB)

Categories: Cancer diseases, Endocrine diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroblastoma

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 12 74 52 25 58 36 29 6 42 43 15 39 17 71
Nb 52 25
Central Neuroblastoma 71
Neuroblastomas 15

Characteristics:

Orphanet epidemiological data:

58
neuroblastoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Childhood; Age of death: adolescent,late childhood;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:769
KEGG 36 H00043
MeSH 43 D009447
NCIt 49 C3270
SNOMED-CT 67 87364003
MESH via Orphanet 44 C536408 D009447
ICD10 via Orphanet 33 C74.9
UMLS via Orphanet 72 C0027819 C2931189
Orphanet 58 ORPHA635
SNOMED-CT via HPO 68 126950007
UMLS 71 C0027819 C0700095

Summaries for Neuroblastoma

MedlinePlus : 42 What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis) How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include A medical history A neurological exam Imaging tests, such as x-rays, a CT scan an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells NIH: National Cancer Institute

MalaCards based summary : Neuroblastoma, also known as nb, is related to neuroblastoma 1 and medulloblastoma, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Transcriptional misregulation in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Itraconazole and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, bone and brain, and related phenotypes are neoplasm of the nervous system and elevated urinary catecholamines

Disease Ontology : 12 An autonomic nervous system neoplasm that derives from immature nerve cells.

Genetics Home Reference : 25 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin. Individuals with neuroblastoma may develop general signs and symptoms such as irritability, fever, tiredness (fatigue), pain, loss of appetite, weight loss, or diarrhea. More specific signs and symptoms depend on the location of the tumor and where it has spread. A tumor in the abdomen can cause abdominal swelling. A tumor in the chest may lead to difficulty breathing. A tumor in the neck can cause nerve damage known as Horner syndrome, which leads to drooping eyelids, small pupils, decreased sweating, and red skin. Tumor metastasis to the bone can cause bone pain, bruises, pale skin, or dark circles around the eyes. Tumors in the backbone can press on the spinal cord and cause weakness, numbness, or paralysis in the arms or legs. A rash of bluish or purplish bumps that look like blueberries indicates that the neuroblastoma has spread to the skin. In addition, neuroblastoma tumors can release hormones that may cause other signs and symptoms such as high blood pressure, rapid heartbeat, flushing of the skin, and sweating. In rare instances, individuals with neuroblastoma may develop opsoclonus myoclonus syndrome, which causes rapid eye movements and jerky muscle motions. This condition occurs when the immune system malfunctions and attacks nerve tissue. Neuroblastoma occurs most often in children before age 5 and rarely occurs in adults.

NIH Rare Diseases : 52 Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue ) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the first month of life. The tumor most often develops in the adrenal gland , but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes ). In most cases, it has spread by the time it is diagnosed. A neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. The cause of most neuroblastomas is not known. Rarely, a neuroblastoma is caused by an inherited mutation in a gene , such as the ALK gene or PHOX2B gene. Diagnosing a neuroblastoma may rely on a physical examination, blood tests, imaging tests (such as MRI or CT scan ) and ultimately, a biopsy . Treatment depends on the size and location of the tumor within the body, as well as the child's age. Surgery is often the first step of treatment, and may be followed by chemotherapy , radiation therapy , or a stem cell transplant in more severe cases. In some children the tumor goes away without treatment. While the long-term outlook and chance of survival depends on many factors, the 5-year survival rate ranges from 40-50% in some, to over 95% in others. The child's doctor is in the best position to provide personalized information about the outlook in each case.

KEGG : 36 Neuroblastoma is a tumor derived from primitive cells of the sympathetic nervous system and is the most common solid tumor in childhood. Approximately one-half of children have localized tumors that can be cured with surgery alone. These favorable tumors are characterized by near-triploid karyotypes with whole chromosome gains. These tumors rarely have structural rearrangements, and they usually express the TrkA neurotrophin receptor. Patients with these tumors are more likely to be less than 1 year of age. The remaining children have widespread metastatic disease or quite large, aggressive, localized tumors. These unfavorable tumors are characterized by structural changes, including deletions of 1p or 11q, unbalanced gain of 17q and/or amplification of the MYCN protooncogene. They might also express the TrkB neurotrophin receptor and its ligand, brain-derived neurotrophic factor (BDNF). These patients are usually older than 1 year of age, and have a poor long-term survival rate of approximately 30%.

Wikipedia : 74 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Related Diseases for Neuroblastoma

Diseases in the Neuroblastoma family:

Neuroblastoma 1 Neuroblastoma 2
Neuroblastoma 3 Neuroblastoma 4
Neuroblastoma 5 Neuroblastoma 6
Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1203)
# Related Disease Score Top Affiliating Genes
1 neuroblastoma 1 35.9 TP53 PTPN11 FGFR1 FANCA ALK
2 medulloblastoma 33.6 TP53 PTPN11 MYCNOS MIR34A MIR17 HOTAIR
3 rhabdomyosarcoma 32.1 TP53 PTPN11 H19 ALK
4 glioma 31.7 TP53 MIR34A MIR184 MIR17 MEG3 HOTAIR
5 astrocytoma 31.5 SNHG1 PTPN11 HOTAIR H19 GAS5 FGFR1
6 lymphoma, non-hodgkin, familial 31.3 TP53 MIR34A MIR17 FGFR1 ALK
7 b-cell lymphoma 31.2 TP53 MIR17 HOTAIR GAS5 ALK
8 leukemia, acute myeloid 31.2 TP53 PTPN11 MIR34A MIR184 MIR17 MEG3
9 embryonal rhabdomyosarcoma 31.2 TP53 PTPN11 H19
10 renal cell carcinoma, nonpapillary 31.1 TP53 NBAT1 MIR34A MIR17 HOTAIR H19
11 hematologic cancer 31.1 TP53 PTPN11 MIR34A MIR17 FGFR1 ALK
12 osteogenic sarcoma 31.0 TP53 SNHG1 MEG3 HOTAIR H19 GAS5
13 melanoma 30.9 TP53 MIR34A MIR184 MIR17 MEG3 HOTAIR
14 glioma susceptibility 1 30.9 TP53 PTPN11 MIR34A MEG3 HOTAIR H19
15 leukemia, chronic lymphocytic 30.7 TP53 PTPN11 MIR34A MIR17 ALK
16 myeloma, multiple 30.7 TP53 PTPN11 MIR17 MEG3 HOTAIR H19
17 diffuse large b-cell lymphoma 30.6 TP53 MIR17 HOTAIR ALK
18 leukemia, chronic myeloid 30.6 TP53 PTPN11 MIR17 MEG3 HOTAIR H19
19 atypical teratoid rhabdoid tumor 30.6 TP53 HOTAIR ALK
20 adrenocortical carcinoma, hereditary 30.6 TP53 MIR184 H19
21 lung cancer 30.5 TP53 SNHG16 SNHG1 MIR34A MIR17 MEG3
22 nasopharyngeal carcinoma 30.5 TP53 MIR17 MEG3 HOTAIR H19 GAS5
23 lung cancer susceptibility 3 30.5 TP53 MIR17 MEG3 HOTAIR H19 GAS5
24 bladder cancer 30.5 TP53 SNHG16 MIR34A MIR17 MEG3 HOTAIR
25 pancreatic cancer 30.4 TP53 MIR34A MIR17 MEG3 HOTAIR H19
26 thyroid cancer, nonmedullary, 1 30.3 HOTAIR HAGLR H19 GAS5
27 ovarian cancer 30.2 TP53 SNHG16 NBAT1 MIR34A MIR184 MIR17
28 gastric cancer 30.1 TP53 SNHG16 SNHG1 PTPN11 MIR34A MIR17
29 hepatocellular carcinoma 30.0 TP53 SNHG1 PTPN11 MIR34A MIR17 MEG3
30 prostate cancer 29.6 TP53 SNHG1 MIR34A MIR184 MIR17 MEG3
31 olfactory neuroblastoma 12.6
32 neuroblastoma 2 12.6
33 neuroblastoma 3 12.6
34 cervical neuroblastoma 12.5
35 cerebral neuroblastoma 12.4
36 adrenal neuroblastoma 12.4
37 nijmegen breakage syndrome 12.4
38 nasal cavity olfactory neuroblastoma 12.3
39 spinal cord neuroblastoma 12.3
40 differentiating neuroblastoma 12.3
41 neuroblastoma 4 12.3
42 neuroblastoma 5 12.3
43 extracranial neuroblastoma 12.3
44 neuroblastoma 6 12.3
45 retroperitoneal neuroblastoma 12.3
46 neuroblastoma 7 12.3
47 obsolete: renal cell carcinoma associated with neuroblastoma 12.3
48 mediastinum neuroblastoma 12.1
49 retinoblastoma 12.0
50 nicolaides-baraitser syndrome 12.0

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma

Symptoms & Phenotypes for Neuroblastoma

Human phenotypes related to Neuroblastoma:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 58 31 hallmark (90%) Very frequent (99-80%) HP:0004375
2 elevated urinary catecholamines 58 31 hallmark (90%) Very frequent (99-80%) HP:0011976

UMLS symptoms related to Neuroblastoma:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Neuroblastoma

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 409)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Panitumumab Approved, Investigational Phase 4 339177-26-3 50070211
4
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
5
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
6
Trametinib Approved Phase 4 871700-17-3 11707110
7
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
8
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
9 Cytochrome P-450 CYP3A Inhibitors Phase 4
10 Cytochrome P-450 Enzyme Inhibitors Phase 4
11 Steroid Synthesis Inhibitors Phase 4
12
Hydroxyitraconazole Phase 4
13 Antimitotic Agents Phase 4
14 Anti-Retroviral Agents Phase 4
15 Antiviral Agents Phase 4
16 Anti-HIV Agents Phase 4
17 Plerixafor octahydrochloride Phase 4
18
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
19
Ethanol Approved Phase 3 64-17-5 702
20
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
21
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
22
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
23
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
24
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
25
Acyclovir Approved Phase 3 59277-89-3 2022
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Captopril Approved Phase 3 62571-86-2 44093
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
31
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
32
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
33
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
34
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
35
Daunorubicin Approved Phase 3 20830-81-3 30323
36
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
37
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
38
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
39
Mycophenolic acid Approved Phase 3 24280-93-1 446541
40
Histamine Approved, Investigational Phase 3 51-45-6 774
41
Cyproheptadine Approved Phase 3 129-03-3 2913
42
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
43
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
44
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
45
Polyestradiol phosphate Approved Phase 3 28014-46-2
46
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
47
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
49
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 618)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
2 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
3 An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Not yet recruiting NCT02006225 Phase 4 Plerixafor
6 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
7 Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
8 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
9 UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)] Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
10 European Infant Neuroblastoma Study Final Protocol Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
11 High Risk Neuroblastoma Study 1 Of Siop-Europe Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
12 NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
13 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
14 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
15 Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
16 Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
17 A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone Completed NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
18 Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
19 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
20 A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy Completed NCT01041638 Phase 3 Isotretinoin
21 Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
22 PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
23 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue Completed NCT00026312 Phase 3 Isotretinoin
24 Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
25 Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma Completed NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
26 A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
27 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
28 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
29 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
30 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
31 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
32 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
33 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
34 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
35 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
38 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
39 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors Completed NCT00243685 Phase 2, Phase 3
40 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
41 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
42 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
43 A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Recruiting NCT03275402 Phase 2, Phase 3
44 Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
45 High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
46 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) Recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane;Dexrazoxane Hydrochloride;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Isotretinoin;Melphalan;Melphalan Hydrochloride;Thiotepa;Topotecan;Topotecan Hydrochloride;Vincristine;Vincristine Sulfate
47 Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma Active, not recruiting NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
48 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
49 Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
50 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Etoposide
etoposide phosphate
Isotretinoin
Melphalan
Melphalan hydrochloride
Vincristine
Vincristine Sulfate

Cochrane evidence based reviews: neuroblastoma

Genetic Tests for Neuroblastoma

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 29 KIF1B

Anatomical Context for Neuroblastoma

MalaCards organs/tissues related to Neuroblastoma:

40
Adrenal Gland, Bone, Brain, Bone Marrow, T Cells, Testes, Kidney

Publications for Neuroblastoma

Articles related to Neuroblastoma:

(show top 50) (show all 31228)
# Title Authors PMID Year
1
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. 61 6
22071890 2012
2
ALK-Related Neuroblastic Tumor Susceptibility 61 6
20301782 2010
3
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. 61 6
18923523 2008
4
Oncogenic mutations of ALK kinase in neuroblastoma. 61 6
18923524 2008
5
Activating mutations in ALK provide a therapeutic target in neuroblastoma. 61 6
18923525 2008
6
Identification of ALK as a major familial neuroblastoma predisposition gene. 61 6
18724359 2008
7
PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. 61 6
16691592 2006
8
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. 61 6
15024693 2004
9
Orbital neuroblastoma metastasis: A case report and literature review. 61 42
31490393 2019
10
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. 61 42
31454045 2019
11
Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report. 61 42
31441848 2019
12
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. 61 46
20841484 2010
13
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. 61 46
19584290 2009
14
Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3' untranslated region: a role for microRNA23b. 61 46
18716031 2008
15
The MYCN oncogene is a direct target of miR-34a. 61 46
18504438 2008
16
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. 61 46
18505919 2008
17
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. 61 46
18493594 2008
18
MYCN regulates oncogenic MicroRNAs in neuroblastoma. 61 46
17943719 2008
19
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. 61 46
17297439 2007
20
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. 61 46
17483472 2007
21
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. 61 46
17283129 2007
22
Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer's disease. 61
31694418 2020
23
Novel tacrine-benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer's Disease. 61
31760822 2020
24
Brain-derived neurotrophic factor mediates macrophage migration inhibitory factor to protect neurons against oxygen-glucose deprivation. 61
31997812 2020
25
The N-formyl peptide receptors: contemporary roles in neuronal function and dysfunction. 61
31960798 2020
26
A mimetic peptide of α2,6-sialyllactose promotes neuritogenesis. 61
31823885 2020
27
Role of miR-124 in the regulation of retinoic acid-induced Neuro-2A cell differentiation. 61
31823894 2020
28
Olfactory neuroblastoma pulmonary metastasis presenting as a solitary pulmonary mass in an adult: A case report with pathologic correlation. 61
31993094 2020
29
A novel risk signature that combines 10 long noncoding RNAs to predict neuroblastoma prognosis. 61
31612488 2020
30
Adult-onset neuroblastoma: Report of seven cases with molecular genetic characterization. 61
31749253 2020
31
Small-world networks of neuroblastoma cells cultured in three-dimensional polymeric scaffolds featuring multi-scale roughness. 61
31638101 2020
32
Metabolomic profiling in neuroblastoma. 61
31802629 2020
33
In vitro assessment of the combination of cylindrospermopsin and the organophosphate chlorpyrifos on the human neuroblastoma SH-SY5Y cell line. 61
31982683 2020
34
Pediatric whole body MRI detects causative ovarian teratoma in opsoclonus myoclonus syndrome. 61
31890069 2020
35
mTORC1 is involved in DGKβ-induced neurite outgrowth and spinogenesis. 61
31891737 2020
36
An Extraordinary Case of Brown Fat Distribution. 61
31833931 2020
37
Pathology of radiation induced heart disease. 61
32021573 2020
38
The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy. 61
31862304 2020
39
PIWI-interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in neuroblastoma cells. 61
31478570 2020
40
Krüppel-like factor 9 promotes neuroblastoma differentiation via targeting the sonic hedgehog signaling pathway. 61
31782614 2020
41
Aged garlic extract and its constituent, S-allyl-L-cysteine, induce the apoptosis of neuroblastoma cancer cells due to mitochondrial membrane depolarization. 61
32010332 2020
42
In vitro and in vivo evaluation of radiolabeled methyl N-[5-(3'-halobenzoyl)-1H-benzimidazol-2-yl]carbamate for cancer radiotherapy. 61
31593323 2020
43
Biological Evaluation of a Potential Anticancer Agent Methyl N-[5-(3'-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate. 61
31687840 2020
44
Retinoic acid receptor gamma is targeted by microRNA-124 and inhibits neurite outgrowth. 61
31170403 2020
45
Neck management in patients with olfactory neuroblastoma. 61
31835073 2020
46
Gestational risk factors and childhood cancers: a cohort study in Taiwan. 61
32020595 2020
47
Approaching the Sella through the Nonpneumatized Sphenoid in Pediatric Patients. 61
32021750 2020
48
Hospital admission for neurologic disorders among 5-year survivors of noncentral nervous system tumors in childhood: A cohort study within the Adult Life after Childhood Cancer in Scandinavia study. 61
30980681 2020
49
Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro. 61
32033253 2020
50
Corrigendum to: NGF protects neuroblastoma cells against β-amyloid induced apoptosis via the Nrf2/HO-1 pathway. 61
32025477 2020

Variations for Neuroblastoma

ClinVar genetic disease variations for Neuroblastoma:

6 (show top 50) (show all 264) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FGFR3 NM_000142.4(FGFR3):c.991T>C (p.Phe331Leu)SNV other 438762 rs1246952737 4:1805479-1805479 4:1803752-1803752
2 MAP2K4 NM_003010.4(MAP2K4):c.538C>G (p.Leu180Val)SNV other 438770 rs1555550018 17:12011131-12011131 17:12107814-12107814
3 MAP2K7 NM_145185.4(MAP2K7):c.752T>C (p.Leu251Pro)SNV other 438771 rs1555701191 19:7975941-7975941 19:7911056-7911056
4 MET NM_001127500.3(MET):c.985C>A (p.Leu329Ile)SNV other 438775 rs1554378983 7:116340123-116340123 7:116700069-116700069
5 NTRK2 NM_006180.4(NTRK2):c.970T>A (p.Leu324Met)SNV other 438780 rs201362502 9:87342685-87342685 9:84727770-84727770
6 PHF6 NM_001015877.2(PHF6):c.119C>A (p.Ala40Glu)SNV other 438782 rs1556013242 X:133511766-133511766 X:134377736-134377736
7 RBM15 NM_022768.4(RBM15):c.1912C>A (p.Gln638Lys)SNV other 438785 rs1553224979 1:110883939-110883939 1:110341317-110341317
8 TSC2 NM_000548.5(TSC2):c.3284+1G>TSNV other 438793 rs45517289 16:2129430-2129430 16:2079429-2079429
9 ALK NM_004304.5(ALK):c.3512T>C (p.Ile1171Thr)SNV Pathogenic 545115 rs1057519698 2:29445213-29445213 2:29222347-29222347
10 FANCA NM_000135.4(FANCA):c.4261-2A>CSNV Pathogenic 545114 rs915983602 16:89805118-89805118 16:89738710-89738710
11 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
12 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
13 ALK NM_004304.5(ALK):c.3512T>A (p.Ile1171Asn)SNV Pathogenic 375888 rs1057519698 2:29445213-29445213 2:29222347-29222347
14 ALK NM_004304.5(ALK):c.3735C>G (p.Phe1245Leu)SNV Pathogenic 375885 rs863225284 2:29436858-29436858 2:29213992-29213992
15 ALK NM_004304.5(ALK):c.3521T>G (p.Phe1174Cys)SNV Pathogenic 375887 rs1057519697 2:29443696-29443696 2:29220830-29220830
16 ALK NM_004304.5(ALK):c.3833A>C (p.Tyr1278Ser)SNV Pathogenic 217858 rs863225285 2:29432655-29432655 2:29209789-29209789
17 ALK NM_004304.5(ALK):c.3734T>G (p.Phe1245Cys)SNV Pathogenic 217856 rs863225283 2:29436859-29436859 2:29213993-29213993
18 ALK NM_004304.5(ALK):c.3520T>A (p.Phe1174Ile)SNV Pathogenic 217850 rs281864719 2:29443697-29443697 2:29220831-29220831
19 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
20 PTPN11 NM_002834.4(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
21 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
22 ALK NM_004304.5(ALK):c.3452C>T (p.Thr1151Met)SNV Pathogenic,risk factor 18086 rs113994091 2:29445273-29445273 2:29222407-29222407
23 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys)SNV Pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
24 ALK NM_004304.5(ALK):c.3520T>G (p.Phe1174Val)SNV Pathogenic 65670 rs281864719 2:29443697-29443697 2:29220831-29220831
25 ALK NM_004304.5(ALK):c.3733T>G (p.Phe1245Val)SNV Pathogenic 65671 rs281864720 2:29436860-29436860 2:29213994-29213994
26 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
27 ALK NM_004304.5(ALK):c.3749T>C (p.Ile1250Thr)SNV Pathogenic/Likely pathogenic 21867 rs113994092 2:29432739-29432739 2:29209873-29209873
28 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln)SNV Pathogenic/Likely pathogenic,risk factor 18083 rs113994087 2:29432664-29432664 2:29209798-29209798
29 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala)SNV Pathogenic/Likely pathogenic,risk factor 18084 rs113994088 2:29445450-29445450 2:29222584-29222584
30 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro)SNV Pathogenic/Likely pathogenic,risk factor 18085 rs113994089 2:29443642-29443642 2:29220776-29220776
31 ALK NM_004304.5(ALK):c.3733T>A (p.Phe1245Ile)SNV Pathogenic/Likely pathogenic 217855 rs281864720 2:29436860-29436860 2:29213994-29213994
32 ALK NM_004304.5(ALK):c.3522C>G (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217852 rs863225281 2:29443695-29443695 2:29220829-29220829
33 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217851 rs863225281 2:29443695-29443695 2:29220829-29220829
34 ALK NM_004304.5(ALK):c.3520T>C (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217849 rs281864719 2:29443697-29443697 2:29220831-29220831
35 PTPN11 NM_002834.4(PTPN11):c.214G>A (p.Ala72Thr)SNV Pathogenic/Likely pathogenic 177754 rs121918453 12:112888198-112888198 12:112450394-112450394
36 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
37 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile)SNV Likely pathogenic 376300 rs756091827 8:128750681-128750681 8:127738435-127738435
38 ALK NM_004304.5(ALK):c.3824G>T (p.Arg1275Leu)SNV Likely pathogenic 376365 rs113994087 2:29432664-29432664 2:29209798-29209798
39 FGFR1 NM_015850.4(FGFR1):c.1630A>G (p.Asn544Asp)SNV Likely pathogenic 376429 rs1057519898 8:38274851-38274851 8:38417333-38417333
40 FGFR1 NM_015850.4(FGFR1):c.1537A>G (p.Met513Val)SNV Likely pathogenic 376430 rs1057519899 8:38275397-38275397 8:38417879-38417879
41 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro)SNV Likely pathogenic 376458 rs750664148 8:128750680-128750680 8:127738434-127738434
42 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu)SNV Likely pathogenic 376459 rs1057519918 8:128750636-128750636 8:127738390-127738390
43 MYCN , MYCNOS NM_005378.6(MYCN):c.131C>T (p.Pro44Leu)SNV Likely pathogenic 376460 rs1057519919 2:16082317-16082317 2:15942195-15942195
44 PIK3CA NM_006218.4(PIK3CA):c.331A>G (p.Lys111Glu)SNV Likely pathogenic 376482 rs1057519933 3:178916944-178916944 3:179199156-179199156
45 PIK3CA NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn)SNV Likely pathogenic 376483 rs1057519934 3:178916946-178916946 3:179199158-179199158
46 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg)SNV Likely pathogenic 376484 rs1057519935 3:178916945-178916945 3:179199157-179199157
47 PTPN11 NM_002834.4(PTPN11):c.215C>A (p.Ala72Asp)SNV Likely pathogenic 376511 rs121918454 12:112888199-112888199 12:112450395-112450395
48 TP53 NM_000546.5(TP53):c.841G>C (p.Asp281His)SNV Likely pathogenic 376588 rs764146326 17:7577097-7577097 17:7673779-7673779
49 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala)SNV Likely pathogenic 376589 rs587781525 17:7577096-7577096 17:7673778-7673778
50 ALK NM_004304.5(ALK):c.3733T>C (p.Phe1245Leu)SNV Likely pathogenic 376712 rs281864720 2:29436860-29436860 2:29213994-29213994

Copy number variations for Neuroblastoma from CNVD:

7 (show top 50) (show all 232)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and loss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2 Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF23 Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification MRVI1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification XLKD1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma

Expression for Neuroblastoma

LifeMap Discovery
Genes differentially expressed in tissues of Neuroblastoma patients vs. healthy controls: 35 (show top 50) (show all 640)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 STAR steroidogenic acute regulatory protein Adrenal Gland - 9.57 0.000
2 CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 Adrenal Gland - 9.02 0.000
3 CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1 Adrenal Gland - 8.90 0.000
4 CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1 Adrenal Gland - 8.90 0.000
5 ELAVL4 ELAV like neuron-specific RNA binding protein 4 Adrenal Gland + 8.22 0.000
6 SULT2A1 sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 Adrenal Gland - 8.16 0.000
7 HAND2 heart and neural crest derivatives expressed 2 Adrenal Gland + 8.05 0.000
8 STMN2 stathmin 2 Adrenal Gland + 7.76 0.000
9 PHOX2B paired-like homeobox 2b Adrenal Gland + 7.74 0.000
10 ISL1 ISL LIM homeobox 1 Adrenal Gland + 7.46 0.000
11 CYP21A2 cytochrome P450, family 21, subfamily A, polypeptide 2 Adrenal Gland - 7.45 0.000
12 MGST1 microsomal glutathione S-transferase 1 Adrenal Gland - 7.39 0.000
13 TUBB2B tubulin, beta 2B class IIb Adrenal Gland + 7.37 0.000
14 NPY neuropeptide Y Adrenal Gland + 7.34 0.000
15 GSTA1 glutathione S-transferase alpha 1 Adrenal Gland - 7.21 0.000
16 RTN1 reticulon 1 Adrenal Gland + 7.18 0.000
17 ADGRV1 adhesion G protein-coupled receptor V1 Adrenal Gland - 7.16 0.000
18 SCG2 secretogranin II Adrenal Gland + 7.15 0.000
19 DCX doublecortin Adrenal Gland + 7.06 0.000
20 NRK Nik related kinase Adrenal Gland - 7.01 0.000
21 MAB21L1 mab-21-like 1 (C. elegans) Adrenal Gland + 7.01 0.000
22 MRAP melanocortin 2 receptor accessory protein Adrenal Gland - 7.01 0.000
23 MGARP mitochondria-localized glutamic acid-rich protein Adrenal Gland - 6.97 0.000
24 SLC38A1 solute carrier family 38, member 1 Adrenal Gland + 6.95 0.000
25 RIMBP2 RIMS binding protein 2 Adrenal Gland + 6.84 0.000
26 CD24 CD24 molecule Adrenal Gland + 6.82 0.000
27 GNRHR gonadotropin-releasing hormone receptor Adrenal Gland - 6.80 0.000
28 LDLR low density lipoprotein receptor Adrenal Gland - 6.79 0.000
29 FDX1 ferredoxin 1 Adrenal Gland - 6.79 0.000
30 HMP19 HMP19 protein Adrenal Gland + 6.78 0.000
31 CPB1 carboxypeptidase B1 (tissue) Adrenal Gland - 6.76 0.000
32 CRMP1 collapsin response mediator protein 1 Adrenal Gland + 6.70 0.000
33 SOX11 SRY (sex determining region Y)-box 11 Adrenal Gland + 6.65 0.000
34 SYT1 synaptotagmin I Adrenal Gland + 6.61 0.000
35 GAP43 growth associated protein 43 Adrenal Gland + 6.61 0.000
36 TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) Adrenal Gland + 6.59 0.000
37 SCN3A sodium channel, voltage gated, type III alpha subunit Adrenal Gland + 6.57 0.000
38 KRT1 keratin 1, type II Blood - 6.56 0.000
39 CELF4 CUGBP, Elav-like family member 4 Adrenal Gland + 6.53 0.000
40 CHGA chromogranin A Adrenal Gland + 6.45 0.000
41 ELAVL2 ELAV like neuron-specific RNA binding protein 2 Adrenal Gland + 6.41 0.000
42 SCARB1 scavenger receptor class B, member 1 Adrenal Gland - 6.33 0.000
43 IGFBPL1 insulin-like growth factor binding protein-like 1 Adrenal Gland + 6.17 0.000
44 INA internexin neuronal intermediate filament protein, alpha Adrenal Gland + 6.16 0.000
45 SNAP91 synaptosomal-associated protein, 91kDa Adrenal Gland + 6.16 0.000
46 CHRNA3 cholinergic receptor, nicotinic, alpha 3 (neuronal) Adrenal Gland + 6.16 0.000
47 PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 Adrenal Gland + 6.15 0.000
48 STMN4 stathmin-like 4 Adrenal Gland + 6.11 0.000
49 SIGLEC11 sialic acid binding Ig-like lectin 11 Adrenal Gland - 6.05 0.000
50 PDZK1IP1 PDZK1 interacting protein 1 Blood - 6.03 0.000
Search GEO for disease gene expression data for Neuroblastoma.

Pathways for Neuroblastoma

Pathways related to Neuroblastoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Neuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.88 TP53 MEG3 HOTAIR

GO Terms for Neuroblastoma

Biological processes related to Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.26 TP53 FGFR1 FANCA ALK
2 positive regulation of cardiac muscle cell apoptotic process GO:0010666 8.8 TP53 MIR34A MIR17

Sources for Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....